3//SEC Filing
BAY CITY CAPITAL LLC 3
Accession 0001179110-18-008863
CIK 0001645666other
Filed
Jun 19, 8:00 PM ET
Accepted
Jun 20, 8:32 PM ET
Size
5.9 KB
Accession
0001179110-18-008863
Insider Transaction Report
Form 3
BAY CITY CAPITAL LLC
10% Owner
Holdings
- (indirect: See footnotes)
Series B Preferred Stock
Exercise: $0.00→ Common Stock (472,229 underlying)
Footnotes (3)
- [F1]Bay City Capital LLC, a Delaware limited liability company (BCC), Bay City Capital JV Management I LLC, a Delaware limited liability company (Management I), Bay City Capital GF XINDE Investment Management Co., a Cayman Islands company (Management Co.), and Bay City Capital GF Xinde International Life Sciences USD Fund, L.P., a Cayman Islands exempt limited partnership (USD Fund) are deemed to be a group for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management Co. is the general partner of USD Fund and has voting and dispositive power with respect to the securities held by USD Fund. BCC is the manager of, and an advisor to, Management I, and Management I holds an equity interest in Management Co.
- [F2]Represent securities held by USD Fund, including indirect interests of BCC, Management I, and Management Co. BCC, Management I and Management Co. each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein.
- [F3]Each share of Series B Preferred Stock will be automatically converted into one share of Common Stock, for no additional consideration, immediately prior to the consummation of the Issuer's initial public offering, and has no expiration date.
Documents
Issuer
Kezar Life Sciences, Inc.
CIK 0001645666
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001288452
Filing Metadata
- Form type
- 3
- Filed
- Jun 19, 8:00 PM ET
- Accepted
- Jun 20, 8:32 PM ET
- Size
- 5.9 KB